The value of dose intensification of standard chemotherapy for advanced breast cancer using colony-stimulating factors alone

Cancer Treatment Reviews

Volumn 24, Issue 3, 1998, Pages 173-184

  Clemons, M ^a   Gharif, R ^a   Howell, A ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADVANCED CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; REVIEW;

EID: 0031712458     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(98)90048-2     Document Type: Article

References (109)

1. Holland JF. Karnofsky memorial lecture: Breaking the cure barrier. J. Clin. Oncol. 1983; 1: 74-90.
2. Baum M, Priestman T, West RR. & Jones E.M. A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast. Eur. J. Cancer Suppl. 1989; 1: 223-226.
3. Skipper HE, Schabel FM, Jary R. & Wilcox WS. Experimental evaluation of antitumour agents. Cancer Chemother. Rep. 1964; 35: 1-34.
4. Giulani FC, Coirin AK, Rice MR. & Kadan NO. Effect of 4-doxorubicin analogues on heterotransplantation of human tumours in congenitively athymic mice. Cancer Treat. Rep. 1981; 65: 1063-1075.
5. Fountizilas G, Lim L. & Yusin AA. Sensitivity to human pancreatic carcinoma cell line (MIA PaCa-Z) bisanterase and theprubicin in vitro In Vitro. 1984; 20: 685-689.
6. Fountizilas G, Inone S. & Ohnuma T. Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mitoxantrone in acute myelogenous leukemia cells in culture. Leukemia 1990; 4: 321-324.
7. Hoogstraten B. Adriamycin (NSC-123127) in the treatment of advanced breast cancer: studies by Southwest Oncology Group. Cancer Chemother. Rep. 1975; 6: 329-339.
8. Frei E. & Canellos OGP. Dose: a critical factor in cancer chemotherapy. Am. J. Med. 1980; 69: 585-594.
9. O'Bryan RM, Baker LH & Gottlieb JE. et al. Dose response evaluation of adriamycin in human neoplasia. Cancer 1977; 39: 1940-1948.
10. Wheeler RH, Ensminger WD, Thrull JH. & Anderson JL. High dose doxorubicin: an exploration of the dose response curve. Cancer Treat. Rev. 1982; 66: 493-498.
11. Hryniuk W. & Bush H. The importance of dose intensity in chemotherapy of breast cancer. J. Clin. Oncol. 1984; 2: 1281-1288.
12. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Import. Adv. Oncol. 1988; 121-141.
13. Frei E. Dose response for adjuvant chemotherapy of breast cancer: experimental and clinical considerations. Recent Results Cancer Res. 1989; 115: 25-7.
14. Fountizilas G, Skarlos D. & Pavlidis N. et al. High dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Cooperative Oncology Group Study. Tumour 1991; 77: 232-236.
15. Bezwoda WR, Dansey R, & Seymour L. High dose 4′ epiadriamycin for the treatment of breast cancer refractory to standard dose anthracycline chemotherapy: achievement of second responses. Oncology 1990; 47: 4-8.
16. Jacobsen P, Basholt L. & Dalmark M. et al. A randomised study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood sample measurement. Cancer Chemother. Pharmacol. 1991; 28: 465-469.
17. Lieschke G.J. & Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N. Eng. J. Med. 1992; 327: 28-35, review article.
18. Herman F, Schulz G. & Linbemenn A. Hematopoietic response in patients with advanced malignancy treated with recombinant human granulocyte- macrophage colony-stimulating factor. J. Clin. Oncol. 1989; 7: 157-167.
19. Asano A. Human granulocyte colony- stimulating factor: Its basic aspects of clinical applications. Am. J. Pediatric Hematol. Oncol. 1991; 13: 400-413.
20. Crawford J, Ozer H, Steller R. et al. Reduction by granulocyte colony-stimulating factor of fever and neutropaenia induced by chemotherapy in patients with small cell lung cancer. N. Eng. J. Med. 1991; 325: 164-170.
21. Trillet-Lenoir V, Green J, Manegold C. et al. rHuG-CSF reduces the infections complications of cytotoxic chemotherapy. Eur. J. Cancer 29A: 319-323.
22. Gisselbrecht C. Chemotherapy dose intensity facilitated by use of lenograstrim - implications for quality of life and survival. Eur. J. Cancer 30 (Suppl. 3): S30-S33.
23. Gisselbrecht C, Prentice HG. & Bacigalupo A. Placebo-controlled phase III trial of lenogastrim in bone marrow transplantation. Lancet 1994; 343: 696-700.
24. Bronchud MH, Potter MR, Morgenstern G. et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte-colony-stimulating factor in patients. Br. J. Cancer 1988; 58: 64-69.
25. Groopman JE, Molina JM. & Scadden DT. Haemopoietic growth factors: biology and clinical applications. N. Eng. J. Med. 1989; 321: 1449-1459.
26. Demetri GD. & Antman KH. Granulocyte macrophage colony-stimulating factor.(GM-CSF): preclinical and clinical investigations. Semin. Oncol. 1992; 4: 362-385.
27. Kaplan LD, Khan JO, Crowe S. et al. Clinical and viralogic effects of recombinant granulocyte-macrophage colony stimulating factor in patients receiving chemotherapy for human immunodeficiency virus associated non-Hodgkins lymphoma: results of a randomised trial. J. Clin. Oncol. 6: 929-940.
28. Rubens RD, Begent RHJ, Knight RK. et al. Combined cytotoxic and progestogen therapy for advanced breast cancer. Cancer 42: 1680-1686.
29. Muss HB, White DR, Richards F. et al. Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. Cancer 1978; 42: 2141-2148.
30. Steiner R, Stewart JF, Cantwell BMJ, Minton MJ, Knight RK. & Rubens RD. Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer. Eur. J. Clin. Oncol. 1983; 19: 1553.
31. Tormey DC, Gelman R, Bond PR. et al. Comparison of induction chemotherapies for metastatic breast cancer. Cancer 50: 1235-1244.
32. Gregory WM, Smith P, Richards MA, Twelves CJ, Knight R. & Rubens RO. Chemotherapy in advanced breast cancer: outcome and prognostic factors. Br. J. Cancer. 1993; 68: 988-995.
33. Perry MC, Kardinal CG, Korzun AH. et al. Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081. J. Clin. Oncol. 1987; 5: 1534-1545.
34. Coates A, Gebski V, Bishop JF. et al. Improving the quality of life during chemotherapy for metastatic. N. Eng. J. Med. 1987; 317: 1490-1495.
35. Italian Multicentre Breast Study with Epirubicin. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer. An Italian multicentre breast study with epirubicin. J. Clin. Oncol. 1988; 6: 976-982.
36. Namer M, Khater R, Hery M. et al. Weekly low dose adriamycin in poor prognosis patients with advanced breast cancer. Breast Cancer Res. Treatment 1986; 8: 92 (abstract).
37. Carmo-Pereira J, Costa FO, Miles DW. et al. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study. Cancer Chemother Pharmacol 1991; 27: 394-396.
38. Richards MA. Hopwood P, Ramirez AJ. et al. Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. Eur. J. Cancer 28A: 1023-1028.
39. Hoogstraten B, George SL, Samal B. et al. Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. Cancer 1976; 38: 13-20.
40. Clark GM, Sledge GW, Osborne CK. et al. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J. Clin. Oncol. 1987; 5: 55-61.
41. Malik R, Blumenschein GR, Legha SS. et al. A randomized trial of high-dose 5-Fu, doxorubicin and cyclophosphamide vs conventional FAC regimen in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 1982; 1: 79 (Abstract).
42. Forastiere AA, Hakes TB, Wittes JT. et al. Cisplatin in the treatment of metastatic breast cancer. A prospective randomised trials of two dosage schedules. Am. J. Clin. Oncol. 1982; 5: 243-247.
43. Beretta G, Tabiadon D, Tedeschi L. et al. Front line treatment with CMF variations for advanced breast carcinoma: a randomized study. Proc. ASCO 77 (abstract 300).
44. Hortobagyi GN, Buzdar AH, Bodey GP. et al. High dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomised study. J. Clin. Onc. 1987; 5: 178-184.
45. Carmo-Pereira J, Costa FO, Henriques E. et al. A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast cancer. Br. J. Cancer 1987; 56: 471-473.
46. Tannock IF, Boyd NF, De Boer G. et al. A randomised trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer. J. Clin. Oncol. 1988; 6: 1377-1387.
47. Ebbs SR, Saunders JA, Graham H, A'Hern RP, Bates T. & Baum M. Advanced breast cancer. A randomised trial of epidoxorubicin at two different dosages and two administration systems. Acta Oncol. 1989; 28: 887-892.
48. Focan C, Andrien JM, Closon MTK, et al. Dose response relationship of epirubicin based first line chemotherapy for advanced breast cancer: a propective randomised trial. J. Clin. Oncol. 1993; 11: 1253 1263.
49. Engelsman E, Klijn JCM, Reubens RD. et al 'Classical' CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. Eur. J. Cancer 1991; 27: 966-970.
50. Habeshaw T, Paul J, Jones R. et al. Epirubicin at two dose levels with prednisolone as treatment of advanced breast cancer. Results of a randomised trial. J. Clin. Oncol. 9: 295-304.
51. French Epirubucin Study Group. A prospective randomised trial comparing epirubicin monochemotherapy to two fluor-uracil, cyclophosphamide and epirabicin regimens differing in epirubicin dose in advance breast cancer patients. J. Clin. Oncol. 9: 305-312.
52. Blomqvist K, Elomma I, Rissanen P. et al. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and flurouracil in metastatic breast cancer: a randomized trial comparing weekly and every 4 week administration. J. Clin. Oncol. 11(3): 467-73.
53. Marschner N, Krelenberg R, Souchon R. et al. Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer. Interim analysis of a prospective randomised trial. Semin Onc. 1994; 21 (Suppl. 1): 10-16.
54. Bastholt L, Dalmark M, Gjedde SB. et al. Dose-response relationship of epirubicin in the treatment of postmenopausal women with metastatic breast cancer: a randomizes study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 14: 1146-1155.
55. Malmstrom P, Malmberg M, Jonsson P-E, Ingvar C, Loven L, Rudenstam C-M. A dose intensity study of epirubicin weekly for disseminated breast cancer. Breast 1997; 6(4): 233-234.
56. Dodwell DJ, Gurney H, Thatcher N. Dose intensity in cancer therapy. Br J Cancer 1990; 61: 789-794 (editorial).
57. Fountzilas G, Skarlos D, Katsohis C. et al. High-dose epirubucin and r-met-hu G-CSF(filgrastim). Med. Pediatr. Oncol. 1995; 24(1), 23-8.
58. Giotta F, Romito S, Gebbia V. et al. L-folinic acid (FA), escalating doses of mitoxanthrone (N), cyclophosphamide (C) and G-CSF in advanced breast cancer patients (ABC). A phase II study. Eur. J. Cancer 1995; 31A: S5, 379 (abstract).
59. O'Brien M, Nicolson M, Montes A. et al. Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor(filgrastim) in patients with advanced breast cancer. Br. J. Cancer 1994; 70: 980-983.
60. O'Shaughnessy J, Denicoff AM, Danforth D. et al Combination chemotherapy with fluorouracil (F), leucovorin(L), adriamycin(A), and cytoxan(C) with granulocytemacrophage colony stimulating factors(GM-CSF) for patients with stage IIB, IIIA, and IIIB locally advanced(LABC) and metastatic(MBC) breast cancer. Proc. Am. Soc. Clin. Oncol. 1991; 10: 72 (abstract 163).
61. O'Shaughnessy J, Denicoff AM, Venzon DJ. et al. A dose intensity study of FLAC (5-fluorouracil(F), leucovorin(L), doxorubicin, cyclophosphamide) chemotherapy and E. coli derived granulocyte-macrophage colony stimulating factors(GM-CSF) advanced breast cancer. Ann. Oncol. 1994; 5(8): 709-716.
62. Muhonen T, Jantunen I, Pertovaara H. et al. Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. Am. J. Clin. Oncol. 1996; 91(3): 232-234.
63. Neidhart J-A. Dose-intensive treatment of breast cancer supported by granulocyte-macrophage colony stimulating factor (GM-CSF). Breast Cancer Res. Treat. 1991; 20: S15-23.
64. Astone A, Ferro A, Torino F. et al. High dose mitoxanthrone and cyclophosphamide with GM-CSF in first line chemotherapy of breast cancer. Eur. J. Cancer 1996; 32A: S2 5-1.
65. Colucci G, Romito S, Gebbia V. et al. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with G-CSF support in locally advanced and/or metasatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group. Br. J. Cancer 1995; 72: 1245-1250.
66. Bitran J, Samuels B, Marsik S. et al. A phase I study of ifosfamide and doxorubicin with recombinant human G-CSF in stage IV breast cancer. Clin. Cancer Res. 1995; 1: 185-188.
67. Iaffaioli RV, Tortoriello A, Facchini G. et al. Phase II study of high dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer. Breast Cancer Res. Treat. 1995; 35: 243-248.
68. Honkoop AH, Hoekman K, Wagstaff J. et al. Dose intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients. Ann. of Oncol. 1996; 7: 35-39.
69. Hoèkman K, Wagstaff J, van Groenigen CJ. et al. Effects of rHuG-CSF on myelosuppression induced by multiple cycles of HDCT in patients with ABC. J. Natl. Cancer Inst. 1991; 83: 1546-1553.
70. Osborne CK, Sunderland MC, Neidhart JA, Ravdin PM, Abeloff MD. Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer. Annals of Oncology 1994; 5: 43-47.
71. Cazap E, Jovtis S, Torchinsky D. et al. Fluorouracil, epirubicin and cyclophosphamide each 14 days with GM-CSF in locally advanced and MBC. Proc ASCO 1997; 164: A572.
72. Pedrazzoli P, Zamagini C, Martoni A. et al. Dose intensification of chemotherapy in advanced breast cancer: a feasibility phase II study. Tumori 1996; 80: 273-275.
73. Lind MJ, Gumbrell L, Cantwell BM. et al. The use of granulocyte-colony stimulating factor to deliver four cycles of ifosfamide and epirubucin every 14 days in women with advanced or metastatic breast cancer. Br. J. Cancer 1995; 71(3): 610-613.
74. Bissette D, Jodrell J, Harnett AN. et al. Phase I study of accelerated FEC with G-CSF (Lenigrastim) support. Br. J. Cancer 1995; 71: 1279-1282.
75. Athanassiou A. Dose intensification by using human recombinant GM-CSF in advanced breast cancer patients. Eur. J. Gynecol. Oncology 1996; 17: 411-413.
76. Fountzilas G, Athanassiades A, Giannakakis T. et al. A randomized study of high-dose epirubicin (E) every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study (ABC). Proc. ASCO 1997; 16: (abstract) 522.
77. Venturini M, Sertoli M, Danova M. et al. Prospective randomised trial of accelerated FEC chemotherapy with or without GM-CSF in advanced breast cancer. Proc. ASCO 1992; 11: 36 (abstract).
78. Ardizzoni A, Venturini M, Sertoli M., et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer. Br. J. Cancer 1994; 96: 385-391.
79. Brochud MH, Howell A, Crowther D. et al. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with ad-vanced breast cancer. Br. J. Cancer 1989; 60: 121-125.
80. Van Hoef Meh, Baumann I, Lange C et al. Dose-escalating induction chemotherapy supported by lenograstin preceding high-dose consolidation chemotherapy for advanced breast cancer. Ann. Oncol. 1994; 5: 217-224.
81. Schmid L, Thurlimann B, Castiglione M. et al. High dose Thio-TT (TT) and epirubicin (EPI) plus RHU-GM-CSF in advanced breast cancer. Eur. J. Cancer 1991; 27 (Suppl. 2): S56 (abstract 309).
82. Piccart M, van der Schueren E, Bruning P. et al. High dose intensity (DI) chemotherapy with epiadriamycin(E), Cyclophosphamide(C), and rmetHuG-CSF(AMGEN) in breast cancer patients. Eur. J. Cancer 1991; 27 (Suppl. 2): S56 (abstract 308).
83. Piccart MJ, Bruning P, & Wilddiers J. An EORTC pilot study of filagrasim (recombinant human granulocye colony stimulating factor) as support to a high dose intensive epiadriamycin-cyclophosphamide regimen in chemotherapy naive patients with locally advanced or metastatic breast cancer. Ann. Oncology 1995; 6: 673-677.
84. Ferguson JE, Dodwell DJ, Seymour AM. et al. High dose, dose intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of breast cancer. Br. J. Cancer 1993; 67: 825-829.
85. Fountzilas G, Skarlos D, Giannakakis T. et al. Intensive chemotherapy with high dose epirubicin every two weeks and prophylactic administration of filgrastim in advanced breast cancer. Eur. J. Cancer 1994; 30(7): 965-969.
86. Nortier J, Wils J, Erdkamp F. et al. Dose dense epirubicin (E) and paditaxel (P) with G-CSF in metastatic breast cancer (MBC). Proc. EORTC 1996; (abstract 7-6).
87. Scinto AF, Cercato MC, Botti C. et al. Phase 2 trial of high dose epirubicin and cyclophosphamide in advanced breast cancer. Eur. J. Cancer 1994; 30A (9): 1285-1288.
88. Scinto AF, Ferraresi V, Campioni N. et al. Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer. Annal. Oncology 1995; 6: 665-671.
89. Bonadonna G, Pannuti F, Robustelli G. et al. Phase III study comparing standard dose FNC versus dose-intensive FNC+HuG-CSF (lenograstim) versus time-intensive FNC+lenograstim in ABC patients. Proc. ASCO 1997; 149: A523.
90. Honkoop AH. & Pinedo HM. High dose chemotherapy in the treatment of breast cancer. Int. J. O. Med. 1995; 6: 911-918.
91. Vici P, Botti C, Conti F, Lauro E, Capoomozlia T. et al CEF + / - GCSF as primary chemotherapy (PCT) in greater than 3cm breast carcinoma (BC). Proc. ASCO 1996;No11 (abstr), 1996.
92. Dreicer R, Jochimsen P, Mayr N. et al. Neoadjuvant VP-16, ifosfamide, cisplatin plus filgrastim and hyperfractionated radiotherapy for inflammatory and locally advanced breast cancer. Proc ASCO 1995; 14: (abstract 267).
93. Artal A, Alonso V, Gallego O. et al FEC-75 plus G-CSF in locally advanced breast carcinoma. Proc. EORTC 1996; (abstract 5-14).
94. Breier S, Lebedinsky C, Giangiacomo G. et al. Intensive chemotherapy with 15 days interdose interval with G-CSF support in locally advanced breast cancer. Proc ASCO 1995; 13: (abstract 188).
95. Smeier B, Labedinsky C, Giangiacom G. et al. Intensive chemotherapy with 15 days interdose interval with G-CSF supporting locally advanced breast cancer patients. Proc. ASCO. 1996; 188.
96. Machaivelli M, Romero A, Cuevas M. et al Multidisciplinary treatments for locally advanced breast carcinoma. Proc. ASCO 1995; 14: A188.
97. Chollet P, Charrier S, Brain E. et al. Neoadjuvant therapy in breast cancer high pathological response rate induced by intensive anthracycline-based regimen. Proc. ASCO 1995; 14: 130.
98. Chevallier B, Chollet P, Merrouche Y. et al. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J. Clin. Oncol. 1995; 13(7): 1564-1571.
99. Lombart-Cussac A, Dohollou N, Rhor A, Janin N. & Le Cesne A. Neo-adjuvant high-dose FEC with G-CSF for Large early breast cancer. Eur J Cancer 1996; 32A: S2 34.
100. Chollet P, Charrier S, Cure H. et al. Neoadjuvant chemotherapy in operable breast cancer. High pathological response rate induced by vinorelbine-anthracycline-based regimen. Proc ASCO 1997; 16: (abstract 573).
101. Bernado C, Plastina M, Bernado A, Strada MR, Dottero G, Berra PG. Neoadjuvant chemotherapy (cyclophosphamide, epirubicin and 5FU) plus G-CSF for operable breast cancer. Proc. ASCO 1995; 125 (abstract 201).
102. Zujweski J, Danforth D, Nonne M. et al. Short course dose intensive, 14 day cycles of doxorubicin (A) and cyclophosphamide (C) followed by infusional pactitaxel (T) in the treatment of high risk primary breast cancer. Proc. ASCO 1996; 145 (abstract).
103. Dhingra K, Singletary E, Strom E. et al. Randomised trial of G-CSF (filgrastrim) supported DI neoadjuvant(neo) chemotherapy in locally advanced breast cancer (LABC). Proc. ASCO 1995; 94 (abstract 76).
104. Graham M, Gonzalez P, Cance S. et al. Dose intensive se-quential adriamycin (A) and IV CMF (A> CMF) with G-CSF (G) support for stage 2 and 3 breast cancer (Br Ca): a feasible and effective output regimen. Proc. ASCO: 1996; 136.
105. McGuire WP. How many more nails to seal the coffin of dose intensity? Ann. Oncology 1997; 8: 311-323 (editorial).
106. Levine L, Hrynick WM. Dose intensify analysis of chemotherapy regimens in ovarian carcinoma. J. Clin. Oncol. 1987; 5: 756-767.
107. Coates A, Gebski V, Signorini D. et al. Prognostic value of quality of life scores during chemotherapy for advanced breast cancer. J. Clin. Oncol. 1992; 10: 1833-1838.
108. Ferry DR, Kerr DJ. Dose intensive data for chemotherapy of ovarian cancer are better described by a saturable model. Br. J. Cancer 1994; 69 (Suppl. 21): 12 (abstract).
109. Focan C, Closon MTH, Andrien JM. et al. Dose response relationship with epirubicin as first line chemotherapy for advanced breast cancer. A randomised trial. Ann. Oncol. 1990; 1: 18 (abstract P3:7).